Legal Notice

Certain statements on this website are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including those that refer to management's plans and expectations for future operations, prospects and financial condition. Words such as "strategy", "expects", "plans", "anticipates", "believes", "will", "continues", "estimates", "intends", "projects", "goals", "targets" and other words of similar meaning are intended to identify such forward-looking statements. One can also identify them by the fact that they do not relate strictly to historical or current facts. Such statements are based on the current expectations of the management of EPI (EndoClot Plus Inc.) only. Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of EndoClot Plus Inc. Actual results could differ materially from current expectations due to a number of factors and uncertainties affecting EndoClot Plus's business, including, but not limited to, a competitive sales and marketing environment, the timely commencement and success of EndoClot Plus's clinical trials and research endeavors, delays in receiving U.S. Food and Drug Administration or other regulatory approvals (e.g., EMEA, CE), market acceptance of EPI's products, effectiveness of EPI's distribution channels, development of competing therapies or technologies, the terms of any future strategic alliances, the need for additional capital and the inability to obtain or meet conditions imposed for the required governmental and regulatory approvals and consents. EPI expressly disclaims any intent or obligation to update these forward-looking statements except as required by law.